Edwards Lifesciences Co. (NYSE:EW) Position Lifted by Parkside Financial Bank & Trust

Parkside Financial Bank & Trust raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 17.1% during the fourth quarter, HoldingsChannel reports. The fund owned 1,125 shares of the medical research company’s stock after acquiring an additional 164 shares during the quarter. Parkside Financial Bank & Trust’s holdings in Edwards Lifesciences were worth $86,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Edwards Lifesciences by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company’s stock worth $3,577,163,000 after buying an additional 325,808 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company’s stock worth $1,138,575,000 after buying an additional 1,390,427 shares during the last quarter. Brown Advisory Inc. lifted its position in shares of Edwards Lifesciences by 5.7% in the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company’s stock worth $1,048,424,000 after buying an additional 818,849 shares during the last quarter. Northern Trust Corp lifted its position in Edwards Lifesciences by 3.9% in the 3rd quarter. Northern Trust Corp now owns 6,357,473 shares of the medical research company’s stock valued at $440,446,000 after purchasing an additional 241,347 shares during the last quarter. Finally, WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST lifted its position in Edwards Lifesciences by 16.8% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,100,000 shares of the medical research company’s stock valued at $312,625,000 after purchasing an additional 590,000 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares in the company, valued at $2,980,774.68. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock valued at $17,166,254 in the last quarter. Insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Mizuho lifted their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Royal Bank of Canada lifted their price objective on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Evercore ISI lifted their price objective on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Finally, Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research report on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Stock Performance

Shares of EW opened at $88.01 on Friday. The firm’s 50 day moving average is $90.27 and its 200-day moving average is $78.76. The stock has a market capitalization of $52.98 billion, a P/E ratio of 38.27, a P/E/G ratio of 4.39 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.